Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
21.60
-1.55 (-6.70%)
Nov 7, 2025, 12:10 PM EST - Market open
Zai Lab Revenue
Zai Lab had revenue of $116.10M in the quarter ending September 30, 2025, with 13.52% growth. This brings the company's revenue in the last twelve months to $441.63M, up 24.14% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$441.63M
Revenue Growth
+24.14%
P/S Ratio
5.64
Revenue / Employee
$236,292
Employees
1,869
Market Cap
2.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZLAB News
- 4 hours ago - Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 7 days ago - Zai Lab Announces Participation in Investor Conferences in November and December 2025 - Business Wire
- 13 days ago - Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript - Seeking Alpha
- 14 days ago - Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
- 23 days ago - Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - Business Wire
- 25 days ago - Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
- 2 months ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga